B
Overview
BiomeSense offers a platform for gut microbiome analysis that combines an at-home biosensor for continuous monitoring with a cloud-based AI-powered analytics system. It enables longitudinal, low-cost data collection for clinical trials and consumer health, moving beyond single-time-point samples. The biosensor gathers microbiome-related data at home and transmits it to the cloud, where AI analyzes trends to generate insights. It differentiates itself by providing an integrated hardware-software solution for large-scale data collection, helping researchers and product developers accelerate precision medicine.
Work here?Claim your company
Simplify's take
What believers are saying
- BiomeSense won a $676,980 NIH SBIR/STTR award in June 2026.
- The October 2025 $7M round added Labcorp Venture Fund and Bluestein Ventures.
- Updated August 2026 website shows active product development and partner messaging.
What critics are saying
- The 2024 Pendulum pilot enrolled only 15 people, proving science, not revenue.
- BiomeSense still lacks broad commercial traction; 2026 evidence shows grants, not scaled contracts.
- If GutLab adoption stalls, larger microbiome platforms and simple sequencing workflows outcompete BiomeSense.
What makes BiomeSense unique
- GutLab and MetaBiome target continuous, longitudinal microbiome data, not single stool snapshots.
- BiomeSense claims 30x more data and up to 90% per-sample cost reduction.
- Pendulum’s 2024 pilot validated home-based serial sampling with BiomeSense's GutLab.
Help us improve and share your feedback! Did you find this helpful?